```
-> b reg
FILE 'REGISTRY' ENTERED AT 17:53:56 ON 16 NOV 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   15 NOV 2007  HIGHEST RN 953991-83-8
DICTIONARY FILE UPDATES:  15 NOV 2007  HIGHEST RN 953991-83-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

-> d que sta l9
L4                  STR
```



```
VAR G1=O/S
VAR G2=13/20/21/22/38
VAR G3=11/13/20/21/22/38/26/28/29/31
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  43

STEREO ATTRIBUTES: NONE
L9          74569 SEA FILE=REGISTRY SSS FUL L4

100.0% PROCESSED  381678 ITERATIONS                     74569 ANSWERS
SEARCH TIME: 00.00.02


-> b hcap
FILE 'HCAPLUS' ENTERED AT 17:54:06 ON 16 NOV 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1907 - 16 Nov 2007 VOL 147 ISS 22
FILE LAST UPDATED: 15 Nov 2007 (20071115/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> d bib abs hitrn 145 fhitstr 146 tot
L46 IS NOT VALID HERE
For an explanation, enter "HELP DISPLAY".

=> d bib abs hitrn 145 fhitstr tot

L45 ANSWER 1 OF 1 HCAPLUS
AN 2004:467859 HCAPLUS
DN 141:38525
TI Preparation of isoindoline derivatives as narcotic drugs
IN Toyooka, Kouhei; Kanamitsu, Norimasa; Yoshimura, Masakazu; Kuriyama, Haruo; Tamura, Takashi
PA Maruishi Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 88 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2004048332	A1	20040610	2003WO-JP14986	20031125
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA---2505029	A1	20040610	2003CA-2505029	20031125
	AU2003284669	A1	20040618	2003AU-0284669	20031125
	JP2004189733	A	20040708	2003JP-0393809	20031125
	EP---1566378	A1	20050824	2003EP-0774195	20031125
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR2003016645	A	20051011	2003BR-0016645	20031125
	CN---1741995	A	20060301	CN 2003-80109189	20031125
	NZ----539834	A	20070831	2003NZ-0539834	20031125
	IN2005DN01967	A	20070713	2005IN-DN01967	20050509
	US2006052392	A1	20060309	2005US-0534414	20050511 <--
	NO2005002529	A	20050623	2005NO-0002529	20050526
PRAI	2002JP-0342399	A	20021126		
	2003WO-JP14986	W	20031125		

OS MARPAT 141:38525
GI


I


II

AB The title compds. I [wherein R1 = 1 to 3 alkyl or alkoxy; or a ring attached to benzene ring; X = O or S; R2 = (un)substituted Ph, PhCH2, pyridyl, etc.; L = (un)substituted -(CH2)n-H, -N(CH2CH2)2N-H, OH, etc.; n = 1-8, with provisos] or salts thereof are prepared as narcotic drugs. For example, the compound II•HCl was prepared in a multi-step synthesis. Some of I showed strong sedative activity in rat.
IT 701301-77-1P 701301-79-3P 701302-63-8P
701302-79-6P 701303-01-7P 701303-79-9P
701304-07-6P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP

L45 ANSWER 1 OF 1 HCAPLUS (Continued)
(Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate, prepn. of isoindoline derivs. as narcotic drugs)
IT 701301-78-2P 701301-80-6P 701301-81-7P
701301-82-8P 701301-83-9P 701301-84-0P
701301-85-1P 701301-86-2P 701301-87-3P
701301-88-4P 701301-89-5P 701301-90-8P
701301-91-9P 701301-92-0P 701301-93-1P
701301-94-2P 701301-95-3P 701301-96-4P
701301-97-5P 701301-98-6P 701301-99-7P
701302-00-3P 701302-01-4P 701302-02-5P
701302-03-6P 701302-04-7P 701302-05-8P
701302-06-9P 701302-07-0P 701302-08-1P
701302-09-2P 701302-10-5P 701302-11-6P
701302-12-7P 701302-13-8P 701302-14-9P
701302-15-0P 701302-16-1P 701302-17-2P
701302-18-3P 701302-19-4P 701302-20-7P
701302-21-8P 701302-22-9P 701302-23-0P
701302-24-1P 701302-25-2P 701302-26-3P
701302-27-4P 701302-28-5P 701302-29-6P
701302-30-9P 701302-31-0P 701302-32-1P
701302-33-2P 701302-34-3P 701302-35-4P
701302-36-5P 701302-37-6P 701302-38-7P
701302-39-8P 701302-40-1P 701302-41-2P
701302-42-3P 701302-43-4P 701302-44-5P
701302-45-6P 701302-46-7P 701302-47-8P
701302-48-9P 701302-49-0P 701302-50-3P
701302-51-4P 701302-52-5P 701302-53-6P
701302-54-7P 701302-55-8P 701302-56-9P
701302-57-0P 701302-58-1P 701302-59-2P
701302-60-5P 701302-61-6P 701302-62-7P
701302-64-9P 701302-65-0P 701302-66-1P
701302-67-2P 701302-68-3P 701302-69-4P
701302-70-7P 701302-71-8P 701302-72-9P
701302-73-0P 701302-74-1P 701302-75-2P
701302-76-3P 701302-77-4P 701302-78-5P
701302-80-9P 701302-81-0P 701302-82-1P
701302-83-2P 701302-84-3P 701302-86-5P
701302-87-6P 701302-89-8P 701302-91-2P
701302-93-4P 701302-95-6P 701302-96-7P
701302-99-0P 701303-03-9P 701303-05-1P
701303-07-3P 701303-09-5P 701303-11-9P
701303-13-1P 701303-15-3P 701303-17-5P
701303-19-7P 701303-21-1P 701303-23-3P
701303-24-4P 701303-25-5P 701303-26-6P
701303-27-7P 701303-28-8P 701303-29-9P
701303-30-2P 701303-31-3P 701303-32-4P
701303-33-5P 701303-34-6P 701303-35-7P
701303-36-8P 701303-37-9P 701303-38-0P
701303-39-1P 701303-40-4P 701303-41-5P
701303-42-6P 701303-43-7P 701303-44-8P
701303-45-9P 701303-46-0P 701303-47-1P
701303-48-2P 701303-49-3P 701303-50-6P
701303-51-7P 701303-52-8P 701303-53-9P
701303-55-1P 701303-56-2P 701303-57-3P
701303-58-4P 701303-59-5P 701303-60-8P
701303-61-9P 701303-62-0P 701303-63-1P
701303-64-2P 701303-65-3P 701303-66-4P
701303-67-5P 701303-68-6P 701303-69-7P
701303-70-0P 701303-72-2P 701303-74-4P
701303-75-5P 701303-76-6P 701303-77-7P
701303-78-8P 701303-80-2P 701303-81-3P
701303-82-4P 701303-83-5P 701303-84-6P
701303-85-7P 701303-86-8P 701303-87-9P
701303-88-0P 701303-89-1P 701303-90-4P
701303-91-5P 701303-92-6P 701303-93-7P
701303-94-8P 701303-95-9P 701303-96-0P
701303-97-1P 701303-98-2P 701303-99-3P
701304-00-9P 701304-01-0P 701304-02-1P
701304-03-2P 701304-04-3P 701304-05-4P
701304-06-5P 701304-08-7P 701304-09-8P

L45 ANSWER 1 OF 1 HCAPLUS (Continued)
701304-10-1P 701304-11-2P 701304-12-3P
701304-13-4P 701304-14-5P 701304-15-6P
701304-16-7P 701304-17-8P 701304-18-9P
701304-19-0P 701304-20-3P 701304-21-4P
701304-22-5P 701304-23-6P 701304-24-7P
701304-25-8P 701304-26-9P 701304-27-0P
701304-28-1P 701304-29-2P 701304-30-5P
701304-31-6P 701304-32-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of isoindoline derivs. as narcotic drugs)
IT 701304-34-9P 701304-35-0P 701304-36-1P
701304-37-2P 701304-38-3P 701304-39-4P
701304-41-8P 701304-43-0P 701304-45-2P
701304-46-3P 701304-47-4P 701304-49-6P
701304-50-9P 701304-51-0P 701304-52-1P
701304-58-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of isoindoline derivs. as narcotic drugs)
IT 701304-55-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of isoindoline derivs. as narcotic drugs)
IT 701301-77-1P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of isoindoline derivs. as narcotic drugs)
RN 701301-77-1 HCAPLUS
CN 1H-Isoindole-1-acetic acid, 2-(4-fluorophenyl)-2,3-dihydro-5,6-dimethyl-3-oxo- (CA INDEX NAME)



RE.CNT 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> d bib abs l46 hitstr tot
```

L46 ANSWER 1 OF 7 HCAPLUS COPYRIGHT 2007 ACS on STN
AN 2007:1092624 HCAPLUS
DN 147:385820
TI Preparation of oxoisoindolinylphenylpropanoates and its analogs for the treatment of spinal muscular atrophy and other uses
IN Heemskerk, Jill; Barnes, Keith D.; McCall, John M.; Johnson, Graham; Fairfax, David; Johnson, Matthew Robert
PA United States Dept. of Health and Human Services, USA; Albany Molecular Research, Inc.; Science Applications International Corporation (SAIC)
SO PCT Int. Appl., 280pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2007109211	A2	20070927	2007WO-US06772	20070313

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GN, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI 2006US-783292P P 20060317
OS MARPAT 147:385820
GI



I



II

AB The title compds. I or II [W = C(O), C(S), CH2; B = CH2, CH(CnH2n+1) (wherein n = 1-8), C = fused thiophene, fused pyridine, cyclohexane (any of which can be saturated or contain one or two non-conjugated double bonds); R1, R2 = H, alkyl, or R1 and R2 may be taken together with the carbon atom to which they are attached to form a cycloalkyl ring or carbonyl group; R3 = H, halo, alkyl, etc.; R4-R7 = H, OH, halo, etc.; with the proviso], useful for the treatment of spinal muscular atrophy or other uses, were prepared and claimed. E.g., a multi-step synthesis of I [B = CH2; W = C(O); R1 = H; R2 = Me; X = CO2H; R6 = Cl; R3-R5, R7 = H], starting from 2-(4-nitrophenyl)propanoic acid, was given. Compds. I and II were tested for their ability to increase SMN expression in cervical carcinoma cell lines (data given for representative compds. I). This invention also relates to methods of using compds. I or II to increase SMN expression, increase ERAT2 expression, or increase the expression of a nucleic acid that encodes a translational stop codon introduced by mutation or frameshift.

L46 ANSWER 1 OF 7 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
IT 950737-69-6P 950739-13-6P 950741-49-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of oxoisoindolinylphenylpropanoates and its analogs for the treatment of spinal muscular atrophy and other uses)
RN 950737-69-6 HCAPLUS
CN Cyclopropanecarboxylic acid, 1-[4-(1,3-dihydro-1-oxo-2H-isoindol-2-yl)phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 950739-13-6 HCAPLUS
CN Benzeneacetic acid, 4-(6-cyclopentyl-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-α-methyl- (CA INDEX NAME)



RN 950741-49-8 HCAPLUS
CN 6H-1,4-Dioxino[2,3-f]isoindol-6-one, 7-(4-cyclohexylphenyl)-2,3,7,8-tetrahydro- (CA INDEX NAME)



L46 ANSWER 2 OF 7 HCAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:1048467 HCAPLUS
DN 146:256
TI Design, synthesis, and evaluation of cyclic amide/imide-bearing hydroxamic acid derivatives as class-selective histone deacetylase (HDAC) inhibitors
AU Shinji, Chihiro; Maeda, Satoko; Imai, Keisuke; Yoshida, Minoru; Hashimoto, Yuichi; Miyachi, Hiroyuki
CS Institute of Molecular and Cellular Biosciences, University of Tokyo, Bunkyo-ku, Tokyo, 113-0032, Japan
SO Bioorganic & Medicinal Chemistry (2006), 14(22), 7625-7651
CODEN: BMECEP, ISSN: 0968-0896
PB Elsevier Ltd.
DT Journal
LA English
OS CASREACT 146:256
GI



I

AB A series of hydroxamic acid derivs. bearing a cyclic amide/imide group as a linker and/or cap structure, prepared during our structural development studies based on thalidomide, showed class-selective potent histone deacetylase (HDAC)-inhibitory activity. Structure-activity relationship studies indicated that the steric character of the substituent introduced at the cyclic amide/imide nitrogen atom, the presence of the amide/imide carbonyl group, the hydroxamic acid structure, the shape of the linking group, and the distance between the zinc-binding hydroxamic acid group and the cap structure are all important for HDAC-inhibitory activity and class selectivity. A representative compound (30w; I) showed potent p21 promoter activity, comparable with that of trichostatin A (TSA), and its cytostatic activity against cells of the human prostate cell line LNCaP was more potent than that of the well-known HDAC inhibitor, suberoylanilide hydroxamic acid (SAHA).
IT 914647-18-0P 914647-19-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(cyclic hydroxamic acid derivs. as histone deacetylase inhibitors with antitumor activity)
RN 914647-18-0 HCAPLUS
CN 2-Propenoic acid, 3-[2-[[2-(1,1-dimethylethyl)phenyl]methyl]-2,3-dihydro-3-oxo-1H-isoindol-5-yl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 914647-19-1 HCAPLUS
CN 2-Propenoic acid, 3-[2-[[4-(1,1-dimethylethyl)phenyl]methyl]-2,3-dihydro-3-oxo-1H-isoindol-5-yl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.

L46 ANSWER 2 OF 7 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L46 ANSWER 3 OF 7 HCAPLUS COPYRIGHT 2007 ACS on STN
AN 2006:268409 HCAPLUS
DN 144:312115
TI Preparation of 3-(piperazinylcarbonylmethyl)isoindole derivatives and anesthetic and sedative compositions containing them
IN Kanemitsu, Norimasa; Itsuji, Hiroshi; Osaki, Takashi; Tsujimoto, Hisashi; Inoue, Keiji
PA Maruishi Pharmaceutical Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 20 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP2006076913	A	20060323	2004JP-0262082	20040909
PRAI	2004JP-0262082		20040909		

OS MARPAT 144:312115
GI



I

AB Claimed are the derivs. I (R1 = Me, 2 R1 groups are bonded to form C2-4 alkylene; R2 = OH, C1-5 saturated aliphatic hydrocarbyl or C3-6 unsatd. hydrocarbyl substituted with C1-3 alkoxy or oxo; X = H, halo) and their salts. The compns. containing I (salts) and carriers are also claimed. The compns. are used by i.v. dosing for induction and maintenance of general anesthesia, management of sedation after operation or in intensive care, etc. Thus, 5,6-indandicarboxylic anhydride (preparation given) was reacted with 3-FC6H4NH2 in AcOH at 135° for 3 h to give 2-(3-fluorophenyl)-6,7-dihydrocyclopenta[f]isoindole-1,3(2H,5H)-dione, which was reduced and the resulting 2-(3-fluorophenyl)-3-hydroxy-3,5,6,7-tetrahydrocyclopenta[f]isoindol-1(2H)-one was reacted with (carboethoxymethylene)triphenylphosphorane to give 2-[2-(3-fluorophenyl)-3-oxo-1,2,3,5,6,7-hexahydrocyclopenta[f]isoindol-1-yl]acetic acid. This was resolved via diastereomeric salt formation with (S)-(-)-phenylethylamine and the (-)-isomer (0.15 g) was amidated with 1-(2-methyl-2-propenyl)piperazine to give 0.15 g (-)-I [R1R1 = (CH2)3, R2 = CH2CMe:CH2, X = 3-F]. Similarly prepared (-)-I.HCl [R1R2 = (CH2)3, R2 = CH2CH:CH2, X = 3-F] showed anesthetic activity with HD50 (min. dose to induce ≥30 s loss of righting reflex in 50% mice) of 1.74 mg/kg, vs. 14.72 mg/kg of propofol.
IT 701304-55-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of (piperazinylcarbonylmethyl)isoindole derivs. and i.v. anesthetic and sedative compns. containing them)
RN 701304-55-4 HCAPLUS
CN 1H-Isoindole-1-acetic acid, 2-(3-fluorophenyl)-2,3-dihydro-5,6-dimethyl-3-oxo- (CA INDEX NAME)



L46 ANSWER 3 OF 7 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

L46 ANSWER 4 OF 7 HCAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:1261054 HCAPLUS
DN 144:6817
TI Preparation of 2-phenyl-2,3-dihydroisoindolin-1-one derivatives and neurogenic pain control agent compositions containing them
IN Yoshimura, Masakazu; Kanamitsu, Norimasa; Itsuji, Yutaka; Osaki, Takashi; Kawashima, Motoko
PA Maruishi Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2005113501	A1	20051201	2005WO-JP09361	20050523
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU2005245292	A1	20051201	2005AU-0245292	20050523
	CA---2563968	A1	20051201	2005CA-2563968	20050523
	EP---1749817	A1	20070207	2005EP-0741421	20050523
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BA, HR, YU				
	CN---1956955	A	20070502	CN 2005-80016837	20050523
	NO2006004868	A	20070226	2006NO-0004868	20061025
	KR2007018077	A	20070213	2006KR-0724401	20061121
PRAI	2004JP-0153206	A	20040524		
	2005WO-JP09361	W	20050523		

OS MARPAT 144:6817
GI



I

AB A neurogenic pain control agent composition containing either a compound represented by the formula (I) [R1, R2 = C1-6 alkyl or R1 and R2 are bonded together to form OCH2O, (CH2)3, CH2OCH2, or a 6-membered condensed ring containing conjugated double bond; X = halo, C1-6 alkoxy or X together with Ph group to which X is bonded form 3,4-methylenedioxyphenyl, m = an integer of 0-2, Y = Q, COR4, cyclopropylmethyl, piperidin-1-yl, wherein R4 = C1-4 alkyl, X = O, S] or a salt thereof is disclosed. The compds. I possess fast analgesic activity against neuropathic pains without affecting motor function. Thus, 2-[2-(3-fluorophenyl)-5,6-dimethyl-3-oxo-2,3-dihydro-1H-isoindol-1-yl]acetic acid 0.50, 1-methylpiperazine 0.16, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride 0.31, 1-hydroxybenzotriazole hydrate 0.25 g were stirred in 40 mL THF at 25° for 16 h to give 5,6-dimethyl-2-(3-fluorophenyl)-3-[[(4-methyl-1-piperazinyl)carbonyl]methyl]isoindolin-1-one. 5,6-Dimethyl-2-(4-fluorophenyl)-3-[[(4-methyl-1-piperazinyl)carbonyl]methyl]isoindolin-1-one monohydrochloride (II) showed analgesic effect on mice at 30 mg/kg p.o. in 5 min after administration and required lower dosage than gabapentin. (-)-II stereoisomer was active but (+)-II stereoisomer was inactive. A

L46 ANSWER 4 OF 7 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
tablet formulation contg. II was described.
IT 701301-77-1P 701302-12-7P 701302-24-1P
701302-26-3P 701302-47-8P 701302-67-2P
701302-68-3P 701302-73-0P 701303-65-3P
701303-72-2P 701303-90-4P 701304-11-2P
RL: BSU (Biological study, unclassified), SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(no analgesic activity; preparation of 2-phenyl-2,3-dihydroisoindolin-2-one derivs. and neurogenic pain control agent compns. containing them)
RN 701301-77-1 HCAPLUS
CN 1H-Isoindole-1-acetic acid, 2-(4-fluorophenyl)-2,3-dihydro-5,6-dimethyl-3-oxo- (CA INDEX NAME)



RN 701302-12-7 HCAPLUS
CN Piperazine, 1-[[2-(4-fluorophenyl)-2,3-dihydro-5,6-dimethyl-3-oxo-1H-isoindol-1-yl]acetyl]-4-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 701302-24-1 HCAPLUS
CN Piperazine, 1-[[2,3-dihydro-5,6-dimethyl-2-(4-methylphenyl)-3-oxo-1H-isoindol-1-yl]acetyl]-4-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 701302-26-3 HCAPLUS
CN Piperazine, 1-[[2-(3,4-dimethylphenyl)-2,3-dihydro-5,6-dimethyl-3-oxo-1H-isoindol-1-yl]acetyl]-4-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

L46 ANSWER 4 OF 7 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



● HCl

RN 701302-47-8 HCAPLUS
CN Piperazine, 1-[(2,3-dihydro-5,6-dimethyl-3-oxo-2-(3-pyridinyl)-1H-isoindol-1-yl]acetyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 701302-67-2 HCAPLUS
CN 4-Piperidinecarboxylic acid, 1-[[2-(4-fluorophenyl)-2,3-dihydro-5,6-dimethyl-3-oxo-1H-isoindol-1-yl]acetyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 701302-68-3 HCAPLUS
CN 4-Piperidinecarboxylic acid, 1-[[2-(4-fluorophenyl)-2,3-dihydro-5,6-dimethyl-3-oxo-1H-isoindol-1-yl]acetyl]- (9CI) (CA INDEX NAME)



L46 ANSWER 4 OF 7 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RN 701302-73-0 HCAPLUS
CN Piperazine, 1-[[2-(2,3-dihydro-1H-inden-5-yl)-2,3-dihydro-5,6-dimethyl-3-oxo-1H-isoindol-1-yl]acetyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 701303-65-3 HCAPLUS
CN 1H-Isoindole-1-acetic acid, 2-(4-fluorophenyl)-2,3-dihydro-5,6-dimethyl-3-oxo-, propyl ester (CA INDEX NAME)



RN 701303-72-2 HCAPLUS
CN 1H-Isoindol-1-one, 2-(4-fluorophenyl)-2,3-dihydro-5,6-dimethyl-3-(2-oxopentyl)- (CA INDEX NAME)



RN 701303-90-4 HCAPLUS
CN 1H-Isoindol-1-one, 2-(4-fluorophenyl)-2,3-dihydro-5,6-dimethyl-3-(2-propoxyethyl)- (CA INDEX NAME)



RN 701304-11-2 HCAPLUS
CN Piperazine, 1-[[[2-(3-fluorophenyl)-2,3-dihydro-5,6-dimethyl-3-oxo-1H-isoindol-1-yl]oxy]acetyl]-4-methyl- (9CI) (CA INDEX NAME)

L46 ANSWER 4 OF 7 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



IT 701301-78-2P 701301-89-5P 701301-90-8P
701301-91-9P 701301-92-0P 701301-93-1P
701301-95-3P 701302-05-8P 701302-18-3P
701302-30-9P 701302-66-1P 701302-74-1P
701304-01-0P 701304-04-3P 701304-06-5P
701304-17-8P 701304-18-9P 870172-33-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2-phenyl-2,3-dihydroisoindolin-2-one derivs. and neurogenic pain control agent compns. containing them)
RN 701301-78-2 HCAPLUS
CN Piperazine, 1-[[2-(3-fluorophenyl)-2,3-dihydro-5,6-dimethyl-3-oxo-1H-isoindol-1-yl]acetyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 701301-89-5 HCAPLUS
CN Piperazine, 1-[(2,3-dihydro-5,6-dimethyl-3-oxo-2-phenyl-1H-isoindol-1-yl)acetyl]-4-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 701301-90-8 HCAPLUS
CN Piperazine, 1-[(2,3-dihydro-5,6-dimethyl-3-oxo-2-phenyl-1H-isoindol-1-yl)acetyl]-4-propyl-, monohydrochloride (9CI) (CA INDEX NAME)

L46 ANSWER 4 OF 7 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



● HCl

RN 701301-91-9 HCAPLUS
CN Piperazine, 1-[(2,3-dihydro-5,6-dimethyl-3-oxo-2-phenyl-1H-isoindol-1-yl)acetyl]-4-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 701301-92-0 HCAPLUS
CN Piperazine, 1-cyclopentyl-4-[(2,3-dihydro-5,6-dimethyl-3-oxo-2-phenyl-1H-isoindol-1-yl)acetyl]- (9CI) (CA INDEX NAME)



RN 701301-93-1 HCAPLUS
CN Piperazine, 1-cyclohexyl-4-[(2,3-dihydro-5,6-dimethyl-3-oxo-2-phenyl-1H-isoindol-1-yl)acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 701301-95-3 HCAPLUS
CN Piperazine, 1-[[2-(3-fluorophenyl)-2,3-dihydro-5,6-dimethyl-3-oxo-1H-isoindol-1-yl]acetyl]-4-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

L44 ANSWER 1 OF 7 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

● HCl

RN 791302-55-8 HCAPLUS
CN Piperazine, 1-[[3-(4-fluorophenyl)-2,3-dihydro-5,6-dimethyl-3-oxo-1H-isoindol-1-yl]acetyl]-4-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

● HCl

RN 791302-38-2 HCAPLUS
CN Piperazine, 1-[[3-(4-chlorophenyl)-2,3-dihydro-5,6-dimethyl-3-oxo-1H-isoindol-1-yl]acetyl]-4-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

● HCl

RN 791302-30-9 HCAPLUS
CN Piperazine, 1-[[2,3-dihydro-3-(4-methoxyphenyl)-5,6-dimethyl-3-oxo-1H-isoindol-1-yl]acetyl]-4-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

● HCl

RN 791302-84-1 HCAPLUS
CN Piperidine, 3-[[2-(4-fluorophenyl)-2,3-dihydro-5,6-dimethyl-3-oxo-1H-

L44 ANSWER 4 OF 7 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 791304-56-5 HCAPLUS
CN Piperazine, 1-(4-fluorophenyl)-2,3-dihydro-3-oxo-1H-benz[f]isoindol-1-yl]acetyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 791304-57-6 HCAPLUS
CN Piperazine, 1-[(2,3-dihydro-5,6-dimethyl-3-oxo-2-phenyl-1H-isoindol-1-yl)acetyl]-4-methyl- (9CI) (CA INDEX NAME)

RN 791304-58-9 HCAPLUS
CN Piperazine, 1-[[3-(4-fluorophenyl)-2,3-dihydro-5,6-dimethyl-3-oxo-1H-isoindol-1-yl]acetyl]-4-methyl- (9CI) (CA INDEX NAME)

RN 870171-33-6 HCAPLUS
CN Piperazine, 3-[[3-[3-fluorophenyl)-1,2,3,4,7-hexahydro-3-oxocyclopent[f]isoindol-1-yl]acetyl]-4-methyl-, monohydrochloride, (+)- (9CI) (CA INDEX NAME)

Rotation (+)

L44 ANSWER 4 OF 7 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

isoindol-1-yl]acetyl]- (9CI) (CA INDEX NAME)

RN 791302-74-1 HCAPLUS
CN Piperazine, 1-[[2-(1,3-benzodioxol-5-yl)-2,3-dihydro-5,6-dimethyl-3-oxo-1H-isoindol-1-yl]acetyl]-4-methyl- (9CI) (CA INDEX NAME)

RN 781304-01-9 HCAPLUS
CN Piperazine, 1-[[2-(3-fluorophenyl)-1,2,3,5,6,7-hexahydro-3-oxocyclopent[f]isoindol-1-yl]acetyl]-4-methyl- (9CI) (CA INDEX NAME)

RN 781304-04-3 HCAPLUS
CN Piperazine, 1-[4-(3-fluorophenyl)-4,7-dihydro-7-oxo-5H-1,3-dioxolo[4,5-f]isoindol-5-yl]acetyl]-4-methyl- (9CI) (CA INDEX NAME)

L44 ANSWER 4 OF 7 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

● HCl

IT 781304-55-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 3-phenyl-2,3-dihydroisoindolin-2-one deriv. and neurogenic 5-HT6 receptor complex. containing them)
RN 781304-55-4 HCAPLUS
CN 1H-Isoindole-1-acetic acid, 5-(3-fluorophenyl)-2,3-dihydro-3,4-dimethyl-3-oxo- (CA INDEX NAME)

RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

AN 2002:879146 HCAPLUS
DN 138:271481
TI A versatile approach for the asymmetric synthesis of 3-alkyl-isoindolin-1-ones
AU Chen, Ming-De; He, Ming-Zhu; Huang, Li-Qiang; Ruan, Yuan-Ping; Huang, Pei-Qiang
CS Department of Chemistry, Xiamen University, Xiamen, 361005, Peop. Rep. China
SO Chinese Journal of Chemistry (2002), 20(11), 1149-1153
CODEN: CJOCEV; ISSN: 1001-604X
PB Science Press
DT Journal
LA English
OS CASREACT 138:271481
AB A flexible approach to (R)-3-alkyl-isoindolin-1-ones and (R)-3-aryl-isoindolin-1-ones via a diastereoselective reductive-alkylation is described. Present method is versatile in scope, allowing the easy introduction of various C-3 substituents by Grignard addition to phthalimide derived from (R)-phenylglycinol. 3-Alkyl-3-hydroxy-isoindolin-1-ones can also be obtained in the first step of the present method
IT 503631-28-5P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(asym. synthesis and crystal structure of alkyl isoindolinones from diastereoselective reductive alkylation involving introduction of C-3 substituents by Grignard addition to phenylglycinol phthalimide compound)
RN 503631-28-5 HCAPLUS
CN 1H-Isoindol-1-one, 3-butyl-2,3-dihydro-2-[(1R)-2-hydroxy-1-phenylethyl]-, (3R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 205380-30-9P 503631-19-4P 503631-23-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(asym. synthesis of alkyl isoindolinones via diastereoselective reductive alkylation involving introduction of C-3 substituents by Grignard addition to phenylglycinol phthalimide compound)
RN 205380-30-9 HCAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[(1R)-2-hydroxy-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 503631-19-4 HCAPLUS
CN 1H-Isoindol-1-one, 2,3-dihydro-3-hydroxy-2-[(1R)-2-hydroxy-1-phenylethyl]-3-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 503631-23-0 HCAPLUS
CN 1H-Isoindol-1-one, 2,3-dihydro-3-hydroxy-2-[(1R)-2-hydroxy-1-phenylethyl]-3-(2-methylpropyl)- (CA INDEX NAME)

Absolute stereochemistry.



IT 290332-72-8P 474088-37-4P 503631-20-7P
503631-21-8P 503631-22-9P 503631-24-1P
503631-25-2P 503631-26-3P 503631-27-4P
503631-29-6P 503631-30-9P 503631-31-0P
503631-32-1P 503631-33-2P 503631-34-3P
503631-35-4P 503631-36-5P 503631-37-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(asym. synthesis of alkyl isoindolinones via diastereoselective reductive alkylation involving introduction of C-3 substituents by Grignard addition to phenylglycinol phthalimide compound)
RN 290332-72-8 HCAPLUS
CN 1H-Isoindol-1-one, 2,3-dihydro-2-[(1R)-2-hydroxy-1-phenylethyl]-3-methyl-, (3R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 474088-37-4 HCAPLUS
CN 1H-Isoindol-1-one, 2,3-dihydro-2-[(1R)-2-hydroxy-1-phenylethyl]-3-(phenylmethyl)-, (3R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 503631-20-7 HCAPLUS
CN 1H-Isoindol-1-one, 2,3-dihydro-3-hydroxy-2-[(1R)-2-hydroxy-1-phenylethyl]-3-phenyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 503631-21-8 HCAPLUS
CN 1H-Isoindol-1-one, 3-ethyl-2,3-dihydro-3-hydroxy-2-[(1R)-2-hydroxy-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 503631-22-9 HCAPLUS
CN 1H-Isoindol-1-one, 3-butyl-2,3-dihydro-3-hydroxy-2-[(1R)-2-hydroxy-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 503631-24-1 HCAPLUS
CN 1H-Isoindol-1-one, 3-heptyl-2,3-dihydro-3-hydroxy-2-[(1R)-2-hydroxy-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 503631-25-2 HCAPLUS
CN 1H-Isoindol-1-one, 2,3-dihydro-3-hydroxy-2-[(1R)-2-hydroxy-1-phenylethyl]-3-(phenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 503631-26-3 HCAPLUS
CN 1H-Isoindol-1-one, 2,3-dihydro-2-[(1R)-2-hydroxy-1-phenylethyl]-3-phenyl-, (3R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 503631-27-4 HCAPLUS
CN 1H-Isoindol-1-one, 3-ethyl-2,3-dihydro-2-[(1R)-2-hydroxy-1-phenylethyl]-, (3R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 503631-29-6 HCAPLUS
CN 1H-Isoindol-1-one, 2,3-dihydro-2-[(1R)-2-hydroxy-1-phenylethyl]-3-(2-methylpropyl)-, (3R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 503631-30-9 HCAPLUS
CN 1H-Isoindol-1-one, 3-heptyl-2,3-dihydro-2-[(1R)-2-hydroxy-1-phenylethyl]-, (3R)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+)



RN 503631-31-0 HCAPLUS
CN 1H-Isoindol-1-one, 2,3-dihydro-2-[(1R)-2-hydroxy-1-phenylethyl]-3-methyl-, (3S)- (CA INDEX NAME)

L46 ANSWER 5 OF 7 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry. Rotation (+).



RN 503631-32-1 HCAPLUS
CN 1H-Isoindol-1-one, 2,3-dihydro-2-[(1R)-2-hydroxy-1-phenylethyl]-3-phenyl-, (3S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 503631-33-2 HCAPLUS
CN 1H-Isoindol-1-one, 3-ethyl-2,3-dihydro-2-[(1R)-2-hydroxy-1-phenylethyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 503631-34-3 HCAPLUS
CN 1H-Isoindol-1-one, 3-butyl-2,3-dihydro-2-[(1R)-2-hydroxy-1-phenylethyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 503631-35-4 HCAPLUS
CN 1H-Isoindol-1-one, 2,3-dihydro-2-[(1R)-2-hydroxy-1-phenylethyl]-3-(2-methylpropyl)-, (3S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

L46 ANSWER 5 OF 7 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 503631-36-5 HCAPLUS
CN 1H-Isoindol-1-one, 3-heptyl-2,3-dihydro-2-[(1R)-2-hydroxy-1-phenylethyl]-, (3S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 503631-37-6 HCAPLUS
CN 1H-Isoindol-1-one, 2,3-dihydro-2-[(1R)-2-hydroxy-1-phenylethyl]-3-(phenylmethyl)-, (3S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RE.CNT 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L46 ANSWER 6 OF 7 HCAPLUS COPYRIGHT 2007 ACS on STN
AN 1998:191496 HCAPLUS
DN 128:270496
TI Synthesis of 3-alkenylisoindolin-1-ones via palladium(0)-catalyzed coupling and cyclization between 2-iodobenzoyl chloride and aldimines
AU Cho, Chan Sik; Wu, Xue; Jiang, Li, Hong; Shim, Sang Chul; Choi, Heung-Jin; Kim, Tae Jeong
CS Dep. of Industrial Chemistry, College of Engineering, Kyungpook National University, Taegu, 702-701, S. Korea
SO Journal of Heterocyclic Chemistry (1998), 35(1), 265-268
CODEN: JHTCAD, ISSN: 0022-152X
PB HeteroCorporation
DT Journal
LA English
OS CASREACT 128:270496
GI

I

AB 2-Iodobenzoyl chloride reacts with aldimines in acetonitrile at 100° under carbon monoxide in the presence of a catalytic amount of bis(triphenylphosphine)palladium(II) chloride together with triethylamine to give the corresponding 3-alkenylisoindolin-1-ones I (R = Bu, iso-Bu, cyclohexyl, R1 = CH2:CMe, Me2C:CH, MeCH:CH) in good yields.
IT 205441-47-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(palladium-catalyzed coupling and cyclization of aldimines and iodobenzoyl chloride to give alkenylisoindolinones)
RN 205441-47-0 HCAPLUS
CN 1H-Isoindol-1-one, 2-cyclohexyl-2,3-dihydro-3-(2-methyl-1-propenyl)- (9CI) (CA INDEX NAME)



RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L46 ANSWER 7 OF 7 HCAPLUS COPYRIGHT 2007 ACS on STN
AN 1979:168453 HCAPLUS
DN 90:168453
TI N-(2,6-Diethylphenyl)-3-imino-1-isoindolinones as agricultural fungicides
IN Takahi, Yukiyoshi; Kondo, Yasuhiko; Tomita, Kazuo
PA Sankyo Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 9 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP--53144570	A	19781215	1977JP-0057269	19770518
PRAI	1977JP-0057269	A	19770518		

GI



I



II

AB Eighteen isoindolinones I (R = H, OH, NH2, Me, N:CMe2, etc., R1 = H, mixed 6(7)-Me), effective against Pellicularia sasakii in rice or Rhizoctonia solani in cucumber seedlings, were prepared e.g. from II. Thus, 2.0 g N-(2,6-diethylphenyl)phthalimide refluxed with 4.03 g P2S5 in xylene for 40 h gave 46.9% II. II stirred with N2H4 in MeOH at room temperature gave 70.9% I (R = NH2, R1 = H), which was converted to I (R = N.CHC6H4Cl-p, R1 = H) in 41.2% yield. II heated with urea at 150-60° for 3 h gave 42.9% I (R = R1 = H), also prepared from o-cyanobenzoyl chloride and 2,6-diethylaniline.
IT 69997-41-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 69997-41-7 HCAPLUS
CN 1H-Isoindol-1-one, 2-(2,6-diethylphenyl)-2,3-dihydro-3-[(3-methylbutyl)imino]- (9CI) (CA INDEX NAME)



```
-> d his

     (FILE 'HOME' ENTERED AT 14:44:32 ON 16 NOV 2007)

     FILE 'HCAPLUS' ENTERED AT 14:44:44 ON 16 NOV 2007
L1             1 US20060052392/PN

     FILE 'REGISTRY' ENTERED AT 14:45:18 ON 16 NOV 2007

     FILE 'HCAPLUS' ENTERED AT 14:45:18 ON 16 NOV 2007
L2             TRA L1 1- RN :      284 TERMS

     FILE 'REGISTRY' ENTERED AT 14:45:18 ON 16 NOV 2007
L3           284 SEA L2
L4               STR
L5            50 L4
L6               STR L4
L7               STR L6
L8             0 L7
L9         74569 L4 FULL
L10            0 L7 SAM SUB=L9
L11            0 L7 FULL SUB=L9
L12          251 L9 AND L3

     FILE 'HCAPLUS' ENTERED AT 16:28:53 ON 16 NOV 2007
L13            3 L12

     FILE 'REGISTRY' ENTERED AT 16:31:58 ON 16 NOV 2007
L14        74318 L9 NOT L12

     FILE 'HCAPLUS' ENTERED AT 16:34:02 ON 16 NOV 2007
L15        29296 L14
L16        24004 L15 AND PD<=20031125
L17        22637 L15 AND PD<=20021125
                 SEL HIT RN 1-20

     FILE 'REGISTRY' ENTERED AT 16:36:21 ON 16 NOV 2007
L18           65 E1-65
L19              STR L4
L20           50 L19 SAM SUB=L9
L21        62778 L19 FULL SUB=L9
L22        11791 L9 NOT L21
                 SAV TEM L22 J414C1/A

     FILE 'HCAPLUS' ENTERED AT 16:38:09 ON 16 NOV 2007
L23         1744 L22 AND L17
                 SEL HIT RN 1-20

     FILE 'REGISTRY' ENTERED AT 16:38:50 ON 16 NOV 2007
L24          156 E66-221
                 DEL SEL Y
L25            4 L24 AND (C20H23NO2 OR C17H12NO2)

     FILE 'HCAPLUS' ENTERED AT 16:42:58 ON 16 NOV 2007
L26            1 L25 AND L23

     FILE 'REGISTRY' ENTERED AT 16:45:50 ON 16 NOV 2007
L27          152 L24 NOT L25

     FILE 'STNGUIDE' ENTERED AT 16:47:09 ON 16 NOV 2007

     FILE 'REGISTRY' ENTERED AT 17:02:46 ON 16 NOV 2007
L28         2259 L22 AND NRRS=3
L29            1 L28 AND C22H22FN3O4

     FILE 'REGISTRY' ENTERED AT 17:17:10 ON 16 NOV 2007

     FILE 'HCAPLUS' ENTERED AT 17:17:13 ON 16 NOV 2007
L30            2 L29
```

```
     FILE 'REGISTRY' ENTERED AT 17:17:48 ON 16 NOV 2007
L31             4 C24H26FN3O2 AND L28

     FILE 'HCAPLUS' ENTERED AT 17:22:49 ON 16 NOV 2007
L32             2 L31

     FILE 'REGISTRY' ENTERED AT 17:23:09 ON 16 NOV 2007
L33            17 L28 AND L3

     FILE 'HCAPLUS' ENTERED AT 17:23:32 ON 16 NOV 2007
L34             2 L33

     FILE 'REGISTRY' ENTERED AT 17:23:58 ON 16 NOV 2007
L35          2242 L28 NOT L33

     FILE 'HCAPLUS' ENTERED AT 17:26:21 ON 16 NOV 2007
L36           226 L35
L37           180 L36 AND (PD<=20031125 OR AD<=20031125 OR PRD<=20031125)
                  SEL HIT RN

     FILE 'REGISTRY' ENTERED AT 17:27:24 ON 16 NOV 2007
L38           762 E1-762

     FILE 'REGISTRY' ENTERED AT 17:49:42 ON 16 NOV 2007
L39             2 L38 AND (C18H23NO OR C23H28N2O OR C22H23NO3)
L40            10 L22 AND (C18H23NO OR C23H28N2O OR C22H23NO3)
L41             8 L40 NOT L39

     FILE 'HCAPLUS' ENTERED AT 17:51:16 ON 16 NOV 2007
L42             4 L41
L43             4 L13,L26,L30
L44             8 L43,L32,L34,L42
L45             1 L44 AND L1
L46             7 L44 NOT L45

-> -> b reg
FILE 'REGISTRY' ENTERED AT 09:14:16 ON 19 NOV 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   18 NOV 2007  HIGHEST RN 954747-20-7
DICTIONARY FILE UPDATES:  18 NOV 2007  HIGHEST RN 954747-20-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

-> d que sta l18
L1              STR
```



VAR G1=O/S
VAR G2=13/20/21/22/38
VAR G3=11/13/20/21/22/38/26/28/29/31
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 43

STEREO ATTRIBUTES: NONE
L2 (74569)SEA FILE=REGISTRY SSS FUL L1
L3 STR



VAR G1=O/S
VAR G2=13/20/21/22/38
VAR G3=11/13/20/21/22/38/26/28/29/31
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 44

STEREO ATTRIBUTES: NONE
L4 (62778)SEA FILE=REGISTRY SUB=L2 SSS FUL L3
L5 11791 SEA FILE=REGISTRY ABB=ON PLU=ON L2 NOT L4

L16 STR



VAR G1=O/S
VAR G2=13/20/21/22/38
VAR G3=11/13/20/21/22/38/26/28/29/31
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED
ECOUNT IS M1 N AT 8

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 37

STEREO ATTRIBUTES: NONE
L18 798 SEA FILE=REGISTRY SUB=L5 SSS FUL L16

100.0% PROCESSED 11791 ITERATIONS 798 ANSWERS
SEARCH TIME: 00.00.01

-> b hcap
FILE 'HCAPLUS' ENTERED AT 09:14:26 ON 19 NOV 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 19 Nov 2007 VOL 147 ISS 22
FILE LAST UPDATED: 18 Nov 2007 (20071118/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

-> d bib abs hitstr l30 tot

AN 1998:682069 HCAPLUS

DN 129:275840

TI Preparation of novel 3,4-dialkoxyphenylisoindolinones and -pyrrolopyridines as tumor necrosis factor-α (TNF-α) inhibitors

IN Baik, Kyong-Up; Yoo, Eun-Sook; Byun, Young-Seok; Lee, Seck-Jong; Jang, Byung-Soo; Son, Ho-Jun; Lee, Jae-Ho; Cho, Jae-Youl; Lee, Se-Jong; Chang, Woo-Ik; Lee, June-goo; Park, Ji-soo; Lee, Byung-goo; Park, Joon-seck; Moon, Seong-cheol; Park, Myung-hwan

PA Daewoong Pharmaceutical Co., Ltd., S. Korea

SO PCT Int. Appl., 88 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO---9842666	A1	19981001	1998WO-KR00048	19980317
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU---9866365	A	19981020	1998AU-0066365	19980317
PRAI	1997KR-0009706	A	19970321		
	1998WO-KR00048	W	19980317		

OS MARPAT 129:275840

GI



I

AB The title compds. [I; X = O, S; A, B, C, D = C, N, N-oxide; R1 = lower alkyl; R2 = lower alkyl, cycloalkyl, hydroxycycloalkyl, etc.; R3 = H, OH; R4 = H, halo, N3, etc.; R5 = H, halo, OH, etc.], having the activity to inhibit tumor necrosis factor-α (TNF-α), and therefore useful in the treatment of inflammatory disease, autoimmune disease, arthritis, asthma, type I diabetes mellitus, etc., were prepared and formulated. Thus, reaction of 2-(3-cyclopentyloxy-4-methoxyphenyl)isoindolin-1,3-dione (preparation described) with MeMgBr in THF followed by treatment of a solution of the resulting 3-methyl-3-hydroxy-2-(3-cyclopentyloxy-4-methoxyphenyl)isoindolin-1-one in CH_2Cl_2 with Et_3SiH and F_3CCO_2H afforded I [X = O, A-D = C, R1 = Me, R2 = cyclopentyl; R3 = H; R4 = Me; R5 = H] which showed 90% inhibitory activity against TNF-α synthesis in vitro

IT 214069-94-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of novel 3,4-dialkoxyphenylindolinones and -pyrrolopyridines as tumor necrosis factor-α (TNF-α) inhibitors)

RN 214069-94-0 HCAPLUS

CN 1H-Isoindol-1-one, 2-[3-(cyclopentyloxy)-4-methoxyphenyl]-2,3-dihydro-3,5,6-trimethyl- (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
-> d his

     (FILE 'HOME' ENTERED AT 08:36:52 ON 19 NOV 2007)

     FILE 'REGISTRY' ENTERED AT 08:37:04 ON 19 NOV 2007
               ACT J414C1/A
               ------------
L1                STR
L2  (     74569)SEA FILE=REGISTRY SSS FUL L1
L3                STR
L4  (     62778)SEA FILE=REGISTRY SUB=L2 SSS FUL L3
L5        11791 SEA FILE=REGISTRY ABB=ON  PLU=ON  L2 NOT L4
               ----------
L6         9532 L5 NOT NRRS=3
L7                STR L3
L8           50 L7 SAM SUB=L5
L9         5127 L7 FULL SUB=L5
L10        3939 L6 AND L9

     FILE 'HCAPLUS' ENTERED AT 08:45:07 ON 19 NOV 2007
L11         619 L10
L12         537 L11 AND (PD<=20031125 OR PRD<=20031125 OR AD<=20031125)
L13         498 L11 AND PD<=20021125
                SEL HIT RN L13
                DEL SEL Y
                SEL HIT RN L13 1-50

     FILE 'REGISTRY' ENTERED AT 08:56:47 ON 19 NOV 2007
L14         165 E1-165
L15         151 L14 NOT NRRS=4

     FILE 'REGISTRY' ENTERED AT 08:59:45 ON 19 NOV 2007
L16               STR L7
L17          38 L16 SAM SUB=L5
L18         798 L16 FULL SUB=L5
L19         405 L18 AND L10

     FILE 'HCAPLUS' ENTERED AT 09:04:18 ON 19 NOV 2007
L20           1 US20060052392/PN

     FILE 'REGISTRY' ENTERED AT 09:04:37 ON 19 NOV 2007

     FILE 'HCAPLUS' ENTERED AT 09:04:38 ON 19 NOV 2007
L21             TRA L20 1- RN :      284 TERMS

     FILE 'REGISTRY' ENTERED AT 09:04:38 ON 19 NOV 2007
L22         284 SEA L21
L23         231 L18 AND L22
L24         175 L19 NOT L23

     FILE 'HCAPLUS' ENTERED AT 09:05:06 ON 19 NOV 2007
L25          31 L24
L26          20 L25 AND (PD<=20031125 OR PRD<=20031125 OR AD<=20031125)
L27          20 L26 NOT L20
                SEL HIT RN

     FILE 'REGISTRY' ENTERED AT 09:06:06 ON 19 NOV 2007
L28          64 E166-229
                DEL SEL Y
L29           1 L28 AND C23H27NO3

     FILE 'HCAPLUS' ENTERED AT 09:13:35 ON 19 NOV 2007
L30           1 L29

-> => b hcap
FILE 'HCAPLUS' ENTERED AT 09:25:01 ON 19 NOV 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1907 - 19 Nov 2007 VOL 147 ISS 22
FILE LAST UPDATED: 18 Nov 2007 (20071118/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> d bib abs hitstr 133

L33 ANSWER 1 OF 1 HCAPLUS
AN 2004:467859 HCAPLUS
DN 141:38525
TI Preparation of isoindoline derivatives as narcotic drugs
IN Toyooka, Kouhei; Kanamitsu, Norimasa; Yoshimura, Masakazu; Kuriyama, Haruo; Tamura, Takashi
PA Maruishi Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 88 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2004048332	A1	20040610	2003WO-JP14986	20031125
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA---2505029	A1	20040610	2003CA-2505029	20031125
	AU2003284669	A1	20040618	2003AU-0284669	20031125
	JP2004189733	A	20040708	2003JP-0393809	20031125
	EP---1566378	A1	20050824	2003EP-0774195	20031125
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR2003016645	A	20051011	2003BR-0016645	20031125
	CN---1741995	A	20060301	CN 2003-80109189	20031125
	NZ----539834	A	20070831	2003NZ-0539834	20031125
	IN2005DN01967	A	20070713	2005IN-DN01967	20050509
	US2006052392	A1	20060309	2005US-0534414	20050511
	NO2005002529	A	20050623	2005NO-0002529	20050526
PRAI	2002JP-0342399	A	20021126		
	2003WO-JP14986	W	20031125		

OS MARPAT 141:38525
GI



I



II

AB The title compds. I [wherein R1 = 1 to 3 alkyl or alkoxy; or a ring attached to benzene ring; X = O or S; R2 = (un)substituted Ph, PhCH2, pyridyl, etc.; L = (un)substituted -(CH2)n-H, -N(CH2CH2)2N-H, OH, etc.; n = 1-8, with provisos] or salts thereof are prepared as narcotic drugs. For example, the compound II•HCl was prepared in a multi-step synthesis. Some of I showed strong sedative activity in rat.
IT 701304-22-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate, prepn. of isoindoline derivs. as narcotic drugs)
RN 701304-22-5 HCAPLUS
CN Piperazine, 1-[(1,2,3,5,6,7-hexahydro-3-oxo-2-phenylcyclopent[f]isoindol-1-yl)acetyl]-4-methyl- (9CI) (CA INDEX NAME)



RE.CNT 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> d his l31-

     (FILE 'REGISTRY' ENTERED AT 09:23:22 ON 19 NOV 2007)
L31         1900 C24H27N3O2
L32            1 L31 AND NC4-C5-C6/ES

     FILE 'HCAPLUS' ENTERED AT 09:24:44 ON 19 NOV 2007
L33            1 L32

=> b hcap
FILE 'HCAPLUS' ENTERED AT 10:21:56 ON 19 NOV 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
the American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 19 Nov 2007  VOL 147 ISS 22
FILE LAST UPDATED: 18 Nov 2007  (20071118/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> d bib abs hitstr 144 tot
```

L44 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2007 ACS on STN

AN 2003:154382 HCAPLUS

DN 138:187795

TI Preparation of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivatives as antagonists of prostaglandin E2 (PEG2) receptors

IN Tani, Kousuke; Asada, Masaki; Kobayashi, Kaoru; Narita, Masami; Ogawa, Mikio

PA Ono Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 1009 pp
CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2003016254	A1	20030227	2002WO-JP08120	20020808
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA---2457468	A1	20030227	2002CA-2457468	20020808
	AU2002323916	A1	20030303	2002AU-0323916	20020808
	EP---1431267	A1	20040623	2002EP-0755874	20020808
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	BR2002011810	A	20040824	2002BR-0011810	20020808
	CN---1551866	A	20041201	2002CN-0817376	20020808
	HU2004001963	A2	20050128	2004HU-0001963	20020808
	NZ----531153	A	20051028	2002NZ-0531153	20020808
	NZ----541950	A	20070223	2002NZ-0541950	20020808
	ZA2004000973	A	20050104	2004ZA-0000973	20040205
	NO2004000564	A	20040510	2004NO-0000564	20040206
	MX2004PA01253	A	20040603	2004MX-PA01253	20040209
	US2006258728	A1	20061116	2004US-0486220	20040909
PRAI	2001JP-0241867	A	20010809		
	2002WO-JP08120	W	20020808		

OS MARPAT 138:187795

GI

I

AB Carboxylic acid derivs. (I) and nontoxic salts thereof [wherein R1 = CO2H, CO2R4, CH2OH, COR5SO2R6, CONH2, CH2NR5SO2R6, CH2NR9COR10, CH2NR9CONR5SO2R6, CH2SO2NR9COR10, CH2O2CNR5SO2R6, tetrazole, 1,2,4-oxadiazol-5-one, 1,2,4-oxadiazol-5-thione, 1,2,4-thiadiazol-5-one, etc. (wherein R4 = C1-6 alkyl, hydroxy-C1-4 alkyl, C1-4 alkoxy-C1-4 alkyl, carboxy-C1-4 alkyl, etc.; R5, R9 = H, C1-6 alkyl; R6 = C1-6 alkyl, C3-15 mono-, di-, or tricarbocyclic, 3- to 13-membered mono-, di-, or tricyclic heterocyclyl, etc.; R10 = H, R6), A = a single bond, C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene, etc.; the ring B = C3-12 mono- or dicyclic carbocyclic ring, 3- to 12-membered mono- or dicyclic heterocyclic ring; R2 = C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, C2-6 alkenyl, C2-6 alkynyl, halo, CHF2, CF3, NO2, cyano, Ph, oxo; m, n = 0,1,2; Q = (C1-4 alkylene, C2-4 alkenylene, or C2-4 alkynylene)-Cyc2, -C1-4 alkylene-Z-Cyc3, amino-C1-4 alkyl, cyano-C1-4 alkyl, acylamino-C1-4 alkyl, 3- to 7-membered monocyclic carbocyclyl, 3- to 6-membered monocyclic heterocyclyl, etc. (wherein Cyc2, Cyc3 = C3-15 mono-, di-, or tricyclic carbocyclyl or heterocyclyl, etc.; Z = O, S, SO, SO2, NH, NHCO, etc.); D = an linking

L44 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

chain consisting of 1-2 or 3-6 of atoms selected from C, N, O, or S, etc.; R3 = C1-6 alkyl, C3-15 mono-, di-, or tricyclic carbocyclyl, 3- to 15-membered mono-, di-, or tricyclic heterocyclyl, etc.] are prepd. These carboxylic acid derivs. include phenylpropanoic acid, phenylpropenoic acid, phenylpropanamide, phenylpropenamide, 3-oxoisoindolin-1-ylacetic acid, benzylbenzoic acid, benzylaminoacetic acid, pyrazolylmethylbenzoic acid, benzoylaminoacetic acid, (pyrazolylmethylphenyl)propenoic acid, pyrazolylmethylpropanoic acid, (pyridinyloxyphenyl)propanoic acid, phenoxyacetic acid, phenylbutanoic acid, (pyrazolylmethyl)propanamide, (piperazinylmethylphenyl)propanamide, (morpholinylmethylphenyl)propanamide, (pyridinyloxyphenyl)propanamide, (pyrazolylmethyl)propenamide (oxoimidazolidinylmethylphenyl)propanamide, (oxopyrrolidinylmethylphenyl)propenamide, (thiophenylmethylphenyl)propenamide, (pyrazolylmethylphenylamino)acetamide, (thiazolylaminomethylphenyl)propanamide, thiophenylpropenamide, (pyrazolylmethylphenoxy)acetamide, (phenoxymethyl)benzamide, (pyrazolylmethylphenylethyl)-1,2,4-oxadiazol-5-one, and (pyrazolylmethylphenylindolyl)acetic acid. Because of binding to PEG2 receptors, in particular, subtype EP3 and/or subtype EP4 and having antagonism, the compds. I are useful in preventing and/or treating diseases such as pain, allodynia, hyperalgesia, pruritus (itching), urticaria, atopic dermatitis, contact dermatitis, Urushi (Japanese lacquer tree) dermatitis, allergic conjunctivitis, symptoms during dialysis, asthma, rhinitis, allergic rhinitis, nasal congestion, sneeze, psoriasis, pollakiuria (increased urinary frequency), urination disorder, ejaculation (semination) disorder, fever (pyrexia), systemic inflammation reaction, learning disorder, Alzheimer's disease, neovascularization, cancer formation, cancer proliferation, cancer metastasis to organs, cancer metastasis to bone, hypercalcemia accompanied by cancer metastasis to bone, retinopathy, rubrum, erytheme (rash), leucoma, skin moth-patch, heat burn, burn, steroid burn, kidney failure, nephropathy, acute or chronic nephritis, blood electrolyte disorder, imminent abortion, threatened abortion, excessive menstruation, dysmenorrhea, endometriosis, premenstrual syndrome, uterine gland myopathy, reprodn. disorder, and stress. They are also useful in preventing and/or treating anxiety, depression, psychophysiol. disorder, mental retardation, thrombus, embolism, transient ischemic attack, cerebral infarction, atheroma, organ transplant, heart failure, hypertension, myocardial infarction, arteriosclerosis, circulation disorders or ulcers assocd. therewith, nerve disorders, vascular dementia, edeme, diarrhea, constipation, biliary excretion disorder, ulcerative colitis, Crohn's disease, irritable bowel syndrome, redn. of rebound after using steroid drugs, aids for decreasing or removing steroid drugs, bone diseases, systemic granuloma, immune diseases, pyorrhea alveolaris, gingivitis, periodontal disease, nerve cell death, lung disorder, liver disorder, acute hepatitis, myocardial ischemia, Kawasaki disease, multiple organ failure, chronic headache, angiitis, venous failure, varicose vein (varicosis), anal fistula, diabetes insipidus, neonatal patent ductus arteriosus, and cholelithiasis. Thus, 4-hydroxymethyl-2-[2-(naphthalen-2-yl)ethoxy]cinnamic acid Et ester was mesylated by methanesulfonyl chloride in the presence of Et3N in THF at 0° for 15 min and condensed with pyrazole in the presence of NaH in DMF at 0° to give 2-[2-(naphthalen-2-yl)ethoxy]-4-(1-pyrazolylmethyl)cinnamic acid Et ester. 4-[2-[[2-(Naphthalen-1-yl)propanoyl]amino]-4-methylthiomethylphenyl]butanoic acid inhibited the binding of [3H]PGE2 to prostaglandin E2 (PEG2) receptor subtype EP1, Ep2, EP3, and EP4 expressed in CHO cells with Ki of >10, >10, 0.27, and 0.038 μM, resp. A tablet formulation contg. (2E)-2-[2-(naphthalen-2-yl)ethoxy]-4-(1-pyrazolylmethyl)cinnamic acid was described.

IT 499154-07-3P 499154-08-4P 499157-17-4P
499157-18-5P 499157-19-6P 499157-20-9P
499157-21-0P 499157-22-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aryl or heterocyclyl-substituted benzoic acid and alkanoic acid derivs. as antagonists of prostaglandin E2 (PEG2) receptors as therapeutic agents)

RN 499154-07-3 HCAPLUS

CN 1H-Isoindole-1-acetamide, N-[(3,4-difluorophenyl)sulfonyl]-2,3-dihydro-2-(1-naphthalenylmethyl)-3-oxo-5-(1H-pyrazol-1-ylmethyl)- (CA INDEX NAME)

L44 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 499154-08-4 HCAPLUS

CN 1H-Isoindole-1-acetamide, N-[(3,4-difluorophenyl)sulfonyl]-2,3-dihydro-2-(3-methyl-1-phenylbutyl)-3-oxo-5-(phenoxymethyl)- (CA INDEX NAME)



RN 499157-17-4 HCAPLUS

CN 1H-Isoindole-1-acetic acid, 2,3-dihydro-5-(hydroxymethyl)-2-(2-naphthalenylmethyl)-3-oxo-, methyl ester (CA INDEX NAME)



RN 499157-18-5 HCAPLUS

CN 1H-Isoindole-1-acetic acid, 2,3-dihydro-2-(2-naphthalenylmethyl)-3-oxo-5-(phenoxymethyl)- (CA INDEX NAME)



RN 499157-19-6 HCAPLUS

L44 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CN 1H-Isoindole-1-acetic acid, 5-[(3-cyanophenoxy)methyl]-2,3-dihydro-2-(2-naphthalenylmethyl)-3-oxo- (CA INDEX NAME)



RN 499157-20-9 HCAPLUS

CN 1H-Isoindole-1-acetic acid, 2,3-dihydro-2-(2-naphthalenylmethyl)-3-oxo-5-(1H-pyrazol-1-ylmethyl)- (CA INDEX NAME)



RN 499157-21-0 HCAPLUS

CN 1H-Isoindole-1-acetic acid, 2,3-dihydro-2-(1-naphthalenylmethyl)-3-oxo-5-(1H-pyrazol-1-ylmethyl)- (CA INDEX NAME)



RN 499157-22-1 HCAPLUS

CN 1H-Isoindole-1-acetic acid, 2,3-dihydro-2-(3-methyl-1-phenylbutyl)-3-oxo-5-(phenoxymethyl)- (CA INDEX NAME)



RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> => d bib abs fhitstr 152 tot
```

L52 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:1261054 HCAPLUS
DN 144:6817
TI Preparation of 2-phenyl-2,3-dihydroisoindolin-1-one derivatives and neurogenic pain control agent compositions containing them
IN Yoshimura, Masakazu; Kanamitsu, Norimasa; Itsuji, Yutaka; Osaki, Takashi; Kawashima, Motoko
PA Maruishi Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2005113501	A1	20051201	2005WO-JP09361	20050523
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU2005245292	A1	20051201	2005AU-0245292	20050523
	CA---2563968	A1	20051201	2005CA-2563968	20050523
	EP---1749817	A1	20070207	2005EP-0741421	20050523
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BA, HR, YU				
	CN---1956955	A	20070502	CN 2005-80016837	20050523
	NO2006004868	A	20070226	2006NO-0004868	20061025
	KR2007018077	A	20070213	2006KR-0724401	20061121
PRAI	2004JP-0153206	A	20040524		
	2005WO-JP09361	W	20050523		

OS MARPAT 144:6817
GI



I



AB A neurogenic pain control agent composition containing either a compound represented by the formula (I) [R1, R2 = C1-6 alkyl or R1 and R2 are bonded together to form OCH2O, (CH2)3, CH2OCH2, or a 6-membered condensed ring containing conjugated double bond; X = halo, C1-6 alkoxy or X together with Ph group to which X is bonded form 3,4-methylenedioxyphenyl; m = an integer of 0-2; Y = Q, COR4, cyclopropylmethyl, piperidin-1-yl; wherein R4 = C1-4 alkyl; X = O, S] or a salt thereof is disclosed. The compds. I possess fast analgesic activity against neuropathic pains without affecting motor function. Thus, 2-[2-(3-fluorophenyl)-5,6-dimethyl-3-oxo-2,3-dihydro-1H-isoindol-1-yl]acetic acid 0.50, 1-methylpiperazine 0.16, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride 0.31, 1-hydroxybenzotriazole hydrate 0.25 g were stirred in 40 mL THF at 25° for 16 h to give 5,6-dimethyl-2-(3-fluorophenyl)-3-[[(4-methyl-1-piperazinyl)carbonyl]methyl]isoindolin-1-one. 5,6-Dimethyl-2-(4-fluorophenyl)-3-[[(4-methyl-1-piperazinyl)carbonyl]methyl]isoindolin-1-one monohydrochloride (II) showed analgesic effect on mice at 30 mg/kg p.o. in

L52 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
5 min after administration and required lower dosage than gabapentin. (-)-II stereoisomer was active but (+)-II stereoisomer was inactive. A tablet formulation contg. II was described
IT 701304-01-0P
RL: PAC (Pharmacological activity), SPN (Synthetic preparation), THU (Therapeutic use), BIOL (Biological study), PREP (Preparation), USES (Uses)
(preparation of 2-phenyl-2,3-dihydroisoindolin-2-one derivs. and neurogenic pain control agent compns. containing them)
RN 701304-01-0 HCAPLUS
CN Piperazine, 1-[[2-(3-fluorophenyl)-1,2,3,5,6,7-hexahydro-3-oxocyclopent[f]isoindol-1-yl]acetyl]-4-methyl- (9CI) (CA INDEX NAME)



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L52 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:467859 HCAPLUS
DN 141:38525
TI Preparation of isoindoline derivatives as narcotic drugs
IN Toyooka, Kouhei; Kanamitsu, Norimasa; Yoshimura, Masakazu; Kuriyama, Haruo, Tamura, Takashi
PA Maruishi Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 88 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2004048332	A1	20040610	2003WO-JP14986	20031125
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA---2505029	A1	20040610	2003CA-2505029	20031125
	AU2003284669	A1	20040618	2003AU-0284669	20031125
	JP2004189733	A	20040708	2003JP-0393809	20031125
	EP---1566378	A1	20050824	2003EP-0774195	20031125
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR2003016645	A	20051011	2003BR-0016645	20031125
	CN---1741995	A	20060301	CN 2003-80109189	20031125
	NZ----539834	A	20070831	2003NZ-0539834	20031125
	IN2005DN01967	A	20070713	2005IN-DN01967	20050509
	US2006052392	A1	20060309	2005US-0534414	20050511
	NO2005002529	A	20050623	2005NO-0002529	20050526
PRAI	2002JP-0342399	A	20021126		
	2003WO-JP14986	W	20031125		

OS MARPAT 141:38525
GI



I



II

AB The title compds. I [wherein R1 = 1 to 3 alkyl or alkoxy, or a ring attached to benzene ring; X = O or S; R2 = (un)substituted Ph, PhCH2, pyridyl, etc.; L = (un)substituted -(CH2)n-H, -N(CH2CH2)2N-H, OH, etc.; n = 1-8; with provisos] or salts thereof are prepared as narcotic drugs. For example, the compound II•HCl was prepared in a multi-step synthesis. Some of I showed strong sedative activity in rat
IT 701304-01-0P
RL: PAC (Pharmacological activity), SPN (Synthetic preparation), THU (Therapeutic use), BIOL (Biological study), PREP (Preparation), USES (Uses)
(drug candidate; preparation of isoindoline derivs. as narcotic drugs)
RN 701304-01-0 HCAPLUS
CN Piperazine, 1-[[2-(3-fluorophenyl)-1,2,3,5,6,7-hexahydro-3-

L52 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
oxocyclopent[f]isoindol-1-yl]acetyl]-4-methyl- (9CI) (CA INDEX NAME)



RE.CNT 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> d his l34-

     (FILE 'HCAPLUS' ENTERED AT 09:24:44 ON 19 NOV 2007)

     FILE 'HCAPLUS' ENTERED AT 09:25:01 ON 19 NOV 2007
                E ANESTHESIA/CT
                E E3+ALL
L34         16237 E5+OLD
L35         11441 E8+OLD,NT
L36         53959 E9+OLD,NT
L37        205755 E10+OLD,NT
L38          3906 E11+OLD,NT
L39         30203 E12+OLD,NT
L40          1149 E13+OLD,NT
L41          1230 E14+OLD,NT
                E ANALGESICS/CT
                E E3+ALL
L42         95645 E5+OLD,NT
L43             3 L25 AND L34-42
                SEL AN 3
L44             1 E1-2 AND L43

     FILE 'REGISTRY' ENTERED AT 10:13:44 ON 19 NOV 2007
L45          2259 L5 NOT L6
L46            61 L45 AND NC4-C5-C6/ES
L47            48 L46 NOT L22

     FILE 'HCAPLUS' ENTERED AT 10:14:51 ON 19 NOV 2007
L48             7 L47
L49             4 L48 AND (PD<=20031125 OR PRD<=20031125 OR AD<=20031125)
                SEL HIT RN

     FILE 'REGISTRY' ENTERED AT 10:16:04 ON 19 NOV 2007
L50            11 E3-13
L51            13 L46 NOT L47

     FILE 'HCAPLUS' ENTERED AT 10:20:50 ON 19 NOV 2007
L52             2 L51

     FILE 'HCAPLUS' ENTERED AT 10:21:56 ON 19 NOV 2007

=> b reg
FILE 'REGISTRY' ENTERED AT 10:56:06 ON 19 NOV 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   18 NOV 2007  HIGHEST RN 954747-20-7
DICTIONARY FILE UPDATES:  18 NOV 2007  HIGHEST RN 954747-20-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> d que sta l63
L1             STR
```





```
VAR G1=O/S
VAR G2=13/20/21/22/38
VAR G3=11/13/20/21/22/38/26/28/29/31
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  43

STEREO ATTRIBUTES: NONE
L2  (      74569)SEA FILE=REGISTRY SSS FUL L1
L3             STR
```





```
VAR G1=O/S
VAR G2=13/20/21/22/38
VAR G3=11/13/20/21/22/38/26/28/29/31
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  44

STEREO ATTRIBUTES: NONE
L4  (      62778)SEA FILE=REGISTRY SUB=L2 SSS FUL L3
L5         11791 SEA FILE=REGISTRY ABB=ON  PLU=ON  L2 NOT L4
L61            STR
```



VAR G1=O/S
VAR G2=13/20/21/22/38
VAR G3=11/13/20/21/22/38/26/28/29/31
VAR G4=38/AK
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 47

STEREO ATTRIBUTES: NONE
L63 298 SEA FILE=REGISTRY SUB=L5 SSS FUL L61

100.0% PROCESSED 771 ITERATIONS 298 ANSWERS
SEARCH TIME: 00.00.01

=> b hcap
FILE 'HCAPLUS' ENTERED AT 10:56:13 ON 19 NOV 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 19 Nov 2007 VOL 147 ISS 22
FILE LAST UPDATED: 18 Nov 2007 (20071118/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

-> d bib abs hitstr l70 tot

AN 1985:184970 HCAPLUS
DN 102:184970
TI Condensed pyrrolinone derivatives
IN Hiraga, Kentaro; Saji, Yoshiaki
PA Takeda Chemical Industries, Ltd. , Japan
SO PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO---8403089	A1	19840816	1983WO-JP00032	19830205
	W: MC				
	EP-----91241	A2	19831012	1983EP-0301656	19830324
	EP-----91241	A3	19840711		
	EP-----91241	B1	19881228		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	US---4590189	A	19860520	1983US-0478478	19830324
	AT-----39483	T	19890115	1983AT-0301656	19830324
	DK---8301369	A	19831003	1983DK-0001369	19830325
	DK----161311	B	19910624		
	DK----161311	C	19911230		
	JP--58189163	A	19831104	1983JP-0057228	19830331
	JP--05002668	B	19930113		
	CA---1196330	A1	19851105	1983CA-0424994	19830331
	HU-----29141	A2	19840130	1983HU-0001142	19830401
	HU----189679	B	19860728		
	SU---1382400	A3	19880315	1983SU-3576799	19830401
	SU---1376941	A3	19880223	1984SU-3773895	19840710
	US---4788191	A	19881129	1986US-0832138	19860423
	US---4879293	A	19891107	1988US-0241851	19880908
PRAI	1982WO-JP00096	A	19820402		
	1982WO-JP00401	A	19821007		
	WO 1982-JP8300032	A	19830205		
	1983WO-JP00032	A	19830205		
	1983EP-0301656	A	19830324		
	1983US-0478478	A3	19830324		
	1986US-0832138	A3	19860423		

GI For diagram(s), see printed CA Issue.

AB Over one hundred title compds. I (R = aryl; R1 = HO, alkoxy, dialkylamino, cyclic amino; Z = CH:CH:CH, SCH2CH2S, N:CHCH:N, C3-5 alkylene; n = 1-3), effective tranquilizers at 0.5-20 mg/day in adults, were prepared. Thus, methylation of 27 g II (R2 = HO) with MeOH in concentrated HCl gave 28 g II (R2 = MeO), which (8.3 g) was treated with 6.7 g CH2(CO2Et)2 over AlCl3 catalyst in ClCH2CH2Cl to give 10.5 g malonate ester II [R2 = (EtO2C)2CH] (III). Heating 10.5 g III with 1.7 g NaH in aqueous Me2SO at 170-180° gave 5.6 g ester II (R2 = EtO2CCH2), which (5 g) was hydrolyzed over 15% K2CO3 to give 3.8 g acid I (R = Ph, R1 = HO, Z = CH:CHCH:CH, n = 1).

IT 88460-25-7P 88460-39-3P 88460-41-7P
88460-43-9P 88460-61-1P
RL: SPN (Synthetic preparation), PREP (Preparation)
(preparation of)

RN 88460-25-7 HCAPLUS
CN Piperazine, 1-[(2,3-dihydro-3-oxo-2-phenyl-1H-isoindol-1-yl)acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 88460-39-3 HCAPLUS
CN Piperazine, 1-[[2-(2-chlorophenyl)-2,3-dihydro-3-oxo-1H-isoindol-1-yl]acetyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 88460-41-7 HCAPLUS
CN Piperazine, 1-[[2-(3-chlorophenyl)-2,3-dihydro-3-oxo-1H-isoindol-1-yl]acetyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 88460-43-9 HCAPLUS
CN Piperazine, 1-[[2-(4-chlorophenyl)-2,3-dihydro-3-oxo-1H-isoindol-1-yl]acetyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 88460-61-1 HCAPLUS
CN Piperazine, 1-[[2-(5-chloro-2-pyridinyl)-2,3-dihydro-3-oxo-1H-isoindol-1-yl]acetyl]-4-methyl- (9CI) (CA INDEX NAME)



AN 1984:490982 HCAPLUS
DN 101:90982
TI Fused pyrrolinone derivatives
IN Hiraga, Kentaro; Saji, Yoshiaki
PA Takeda Chemical Industries, Ltd. , Japan
SO PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO---8401576	A1	19840426	1982WO-JP00401	19821007
	W: MC				
	EP-----91241	A2	19831012	1983EP-0301656	19830324
	EP-----91241	A3	19840711		
	EP-----91241	B1	19881228		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	US---4590189	A	19860520	1983US-0478478	19830324
	AT-----39483	T	19890115	1983AT-0301656	19830324
	DK---8301369	A	19831003	1983DK-0001369	19830325
	DK----161311	B	19910624		
	DK----161311	C	19911230		
	JP--58189163	A	19831104	1983JP-0057228	19830331
	JP--05002668	B	19930113		
	CA---1196330	A1	19851105	1983CA-0424994	19830331
	HU-----29141	A2	19840130	1983HU-0001142	19830401
	HU----189679	B	19860728		
	SU---1382400	A3	19880315	1983SU-3576799	19830401
	SU---1376941	A3	19880223	1984SU-3773895	19840710
	US---4788191	A	19881129	1986US-0832138	19860423
	US---4879293	A	19891107	1988US-0241851	19880908
PRAI	1982WO-JP00096	A	19820402		
	1982WO-JP00401	A	19821007		
	WO 1982-JP8300032	A	19830205		
	1983WO-JP00032	A	19830205		
	1983EP-0301656	A	19830324		
	1983US-0478478	A3	19830324		
	1986US-0832138	A3	19860423		

GI For diagram(s), see printed CA Issue

AB Title compds. I [R = (un)substituted Ph; R1 = optionally esterified or amidated carboxyl group; Z = CH:CHCH:CH, S(CH2)lS, N:CHCH:N, (CH2)m, l = 1-3, m = 3-5, n = 1-3], useful as anxiolytics (deta shown on benzodiazepine receptor binding), were prepared. Thus, O-methylation of 3-hydroxy-2-phenylisoindolin-1-one with MeOH followed by treatment with CH2(CO2Et)2 gave di-Et 3-oxo-2-phenylisoindolin-1-malonate which was deethoxycarbonylated and hydrolyzed to give isoindolinone II.

IT 88460-25-7P 88460-39-3P 88460-41-7P
88460-43-9P 88460-61-1P
RL: SPN (Synthetic preparation), PREP (Preparation)
(preparation of)

RN 88460-25-7 HCAPLUS
CN Piperazine, 1-[(2,3-dihydro-3-oxo-2-phenyl-1H-isoindol-1-yl)acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 88460-39-3 HCAPLUS
CN Piperazine, 1-[[2-(2-chlorophenyl)-2,3-dihydro-3-oxo-1H-isoindol-1-yl]acetyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 88460-41-7 HCAPLUS
CN Piperazine, 1-[[2-(3-chlorophenyl)-2,3-dihydro-3-oxo-1H-isoindol-1-yl]acetyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 88460-43-9 HCAPLUS
CN Piperazine, 1-[[2-(4-chlorophenyl)-2,3-dihydro-3-oxo-1H-isoindol-1-yl]acetyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 88460-61-1 HCAPLUS
CN Piperazine, 1-[[2-(5-chloro-2-pyridinyl)-2,3-dihydro-3-oxo-1H-isoindol-1-yl]acetyl]-4-methyl- (9CI) (CA INDEX NAME)



AN 1984:51451 HCAPLUS
DN 100:51451
TI Isoindoline derivatives
IN Hiraga, Kentaro; Saji, Yoshiaki
PA Takeda Chemical Industries, Ltd., Japan
SO PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO---8303410	A1	19831013	1982WO-JP00096	19820402
	W: MC				
	EP-----91241	A2	19831012	1983EP-0301656	19830324
	EP-----91241	A3	19840711		
	EP-----91241	B1	19881228		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	US---4590189	A	19860520	1983US-0478478	19830324
	AT-----39483	T	19890115	1983AT-0301656	19830324
	DK---8301369	A	19831003	1983DK-0001369	19830325
	DK----161311	B	19910624		
	DK----161311	C	19911230		
	JP--58189163	A	19831104	1983JP-0057228	19830331
	JP--05002668	B	19930113		
	CA---1196330	A1	19851105	1983CA-0424994	19830331
	HU-----29141	A2	19840130	1983HU-0001142	19830401
	HU----189679	B	19860728		
	SU---1376941	A3	19880223	1984SU-3773895	19840710
	US---4788191	A	19881129	1986US-0832138	19860423
	US---4879293	A	19891107	1988US-0241851	19880908
PRAI	1982WO-JP00096	A	19820402		
	1982WO-JP00401	A	19821007		
	WO 1982-JP8300032	A	19830205		
	1983WO-JP00032	A	19830205		
	1983EP-0301656	A	19830324		
	1983US-0478478	A3	19830324		
	1986US-0832138	A3	19860423		

OS MARPAT 100:51451
GI



AB Isoindolines I [R = (un)substituted Ph, halopyridyl; R1 = optionally esterified or amidated carboxy group; Z= alkylene], useful as anxiolytics (benzodiazepine receptor binding data was given), were prepared. Thus, condensation of 3-methoxy-2-phenylisoindolin-1-one with CH2(CO2Et)2 followed by decarboxylation gave isoindolineacetate II (R2 = Et). Hydrolysis of the latter compound gave II (R2 = H).
IT 88460-25-7P 88460-39-3P 88460-41-7P
88460-43-9P 88460-61-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 88460-25-7 HCAPLUS
CN Piperazine, 1-[(2,3-dihydro-3-oxo-2-phenyl-1H-isoindol-1-yl)acetyl]-, monohydrochloride (9CI) (CA INDEX NAME)



RN 88460-39-3 HCAPLUS
CN Piperazine, 1-[[2-(2-chlorophenyl)-2,3-dihydro-3-oxo-1H-isoindol-1-yl]acetyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 88460-41-7 HCAPLUS
CN Piperazine, 1-[[2-(3-chlorophenyl)-2,3-dihydro-3-oxo-1H-isoindol-1-yl]acetyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 88460-43-9 HCAPLUS
CN Piperazine, 1-[[2-(4-chlorophenyl)-2,3-dihydro-3-oxo-1H-isoindol-1-yl]acetyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 88460-61-1 HCAPLUS
CN Piperazine, 1-[[2-(5-chloro-2-pyridinyl)-2,3-dihydro-3-oxo-1H-isoindol-1-yl]acetyl]-4-methyl- (9CI) (CA INDEX NAME)



```
=> d his l53-

     (FILE 'HCAPLUS' ENTERED AT 10:20:50 ON 19 NOV 2007)

     FILE 'REGISTRY' ENTERED AT 10:31:13 ON 19 NOV 2007
L53            8 E1-8
L54           60 L5 AND (OCOC2-NC4-C6 OR NC4-OC4-C6)/ES
L55            2 L54 AND L22

     FILE 'HCAPLUS' ENTERED AT 10:38:10 ON 19 NOV 2007
L56            2 L55

     FILE 'REGISTRY' ENTERED AT 10:38:40 ON 19 NOV 2007
L57           58 L54 NOT L55

     FILE 'HCAPLUS' ENTERED AT 10:38:47 ON 19 NOV 2007
L58           18 L57
L59            7 (PD<=20031125 OR PRD<=20031125 OR AD<=20031125) AND L58
                 SEL HIT RN

     FILE 'REGISTRY' ENTERED AT 10:39:51 ON 19 NOV 2007
L60           25 E9-33
L61              STR L3
L62           20 L61 SAM SUB=L5
L63          298 L61 FULL SUB=L5
L64          116 L22 AND L63
L65          182 L63 NOT L64

     FILE 'HCAPLUS' ENTERED AT 10:47:21 ON 19 NOV 2007
L66           43 L65
L67           33 (PD<=20031125 OR PRD<=20031125 OR AD<=20031125) AND L66
                 SEL HIT RN

     FILE 'REGISTRY' ENTERED AT 10:47:56 ON 19 NOV 2007
L68           71 E34-104
L69            5 L68 AND (C21H22CLN3O2 OR C20H21CLN4O2 OR C20H21N3O2)

     FILE 'HCAPLUS' ENTERED AT 10:54:03 ON 19 NOV 2007
L70            3 L69
L71            0 L34-42 AND L70
L72          359 L5 AND L34-42

=>
```